当前位置: X-MOL 学术Health Economics Review › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development of a pharmacoeconomic registry: an example using hormonal contraceptives.
Health Economics Review ( IF 2.7 ) Pub Date : 2021-03-20 , DOI: 10.1186/s13561-021-00309-z
Annesha White 1, 2 , Meenakshi Srinivasan 1 , La Marcus Wingate 3 , Samuel Peasah 4 , Marc Fleming 1
Affiliation  

BACKGROUND Disease-specific registries, documenting costs and probabilities from pharmacoeconomic studies along with health state utility values from quality-of-life studies could serve as a resource to guide researchers in evaluating the published literature and in the conduct of future economic evaluations for their own research. Registries cataloging economic evaluations currently exist, however they are restricted by the type of economic evaluations they include. There is a need for intervention-specific registries, that document all types of complete and partial economic evaluations and auxiliary information such as quality of life studies. The objective of this study is to describe the development of a pharmacoeconomic registry and provide best practices using an example of hormonal contraceptives. METHODS An expert panel consisting of researchers with expertise in pharmacoeconomics and outcomes research was convened and the clinical focus of the registry was finalized after extensive discussion. A list of key continuous, categorical and descriptive variables was developed to capture all relevant data with each variable defined in a data dictionary. A web-based data collection tool was designed to capture and store the resulting metadata. A keyword based search strategy was developed to retrieve the published sources of literature. Finally, articles were screened for relevancy and data was extracted to populate the registry. Expert opinions were taken from the panel at each stage to arrive at consensus and ensure validity of the registry. RESULTS The registry focused on economic evaluation literature of hormonal contraceptives used for contraception. The registry consisted of 65 articles comprising of 22 cost-effectiveness analyses, 9 cost-utility analyses, 7 cost-benefit analyses, 1 cost-minimization, 14 cost analyses, 10 cost of illness studies and 2 quality of life studies. The best practices followed in the development of the registry were summarized as recommendations. The completed registry, data dictionary and associated data files can be accessed in the supplementary information files. CONCLUSION This registry is a comprehensive database of economic evaluations, including costs, clinical probabilities and health-state utility estimates. The collated data captured from published information in this registry can be used to identify trends in the literature, conduct systematic reviews and meta-analysis and develop novel pharmacoeconomic models.

中文翻译:

药物经济学资料库的开发:使用荷尔蒙避孕药的例子。

背景技术特定疾病的登记簿,药物经济学研究的成本和概率以及生活质量研究的健康状态效用值的文档化,可作为指导研究人员评估已发表文献和进行自身未来经济评估的资源。研究。当前存在对经济评估进行分类的注册管理机构,但是它们受到其所包括的经济评估类型的限制。需要专门针对干预措施的注册表,该注册表记录所有类型的完整和部分经济评估以及诸如生活质量研究之类的辅助信息。这项研究的目的是描述荷尔蒙避孕药的开发,并提供最佳实践。方法召集由在药物经济学和结果研究方面具有专业知识的研究人员组成的专家小组,并在广泛讨论后最终确定了注册中心的临床重点。开发了一个关键的连续,分类和描述性变量的列表,以捕获所有相关数据,并在数据字典中定义每个变量。设计了一个基于Web的数据收集工具,以捕获和存储生成的元数据。开发了基于关键字的搜索策略以检索已出版的文献资源。最后,筛选文章的相关性,并提取数据以填充注册表。在每个阶段均从小组中获取专家意见,以达成共识并确保注册表的有效性。结果该注册表集中于用于避孕的激素避孕药的经济评估文献。该注册表由65篇文章组成,包括22项成本效益分析,9项成本效用分析,7项成本效益分析,1项成本最小化,14项成本分析,10项疾病成本研究和2项生活质量研究。总结了注册表开发过程中遵循的最佳实践,作为建议。完整的注册表,数据字典和关联的数据文件可以在补充信息文件中访问。结论该注册表是经济评估的综合数据库,包括成本,临床概率和健康状态效用估算。从该注册表中已发布信息中收集的整理数据可用于识别文献中的趋势,
更新日期:2021-03-20
down
wechat
bug